Synovial Fibroblast 3.1: Secretion response of seven primary human synovial fibroblast samples from healthy and rheumatoid arthritis donors to a panel of 3 stimuli and 5 small molecule inhibitors (replicate 1 of 2) - Dataset (ID:20234)
- Detail
- Small Molecules Studied
- Primary Cells Studied
- Proteins Studied
- Unclassified Perturbagens Studied
- Data Columns
- Results
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Protein Stimulus | Other Stimulus | Stimulus Concentration | Stimulus Conc Unit | ExpPlate | Measured Protein | Measured Protein MFI (a.u.) | Bead Count |
|---|---|---|---|---|---|---|---|---|---|---|---|
| N2759 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 92.0 | 58 | |
| RA1931 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 95.5 | 58 | |
| RA1931 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 859.0 | 50 | |
| N2586 | 5z-7-oxozeaenol | 0.6 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 205.0 | 49 | |
| N2586 | IKK16 | 2.0 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 535.5 | 56 | |
| RA1869 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 4458.0 | 46 | |
| RA1869 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 7255.0 | 62 | ||||
| N2759 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 3702.0 | 56 | |
| N2759 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 3941.0 | 55 | ||||
| RA1931 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 4546.5 | 56 | |
| RA1931 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 5841.0 | 42 | ||||
| N2586 | Tofacitinib | 0.3 | uM | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 5072.0 | 47 | |
| N2586 | Poly(I:C) | 2 | ug/mL | 3 | MCP-1 (MCAF) | 4818.0 | 39 | ||||
| RA1869 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 92.5 | 60 | |
| RA1869 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 1489.0 | 39 | |
| N2759 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 75.5 | 52 | |
| N2759 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 328.0 | 54 | |
| RA1931 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 93.0 | 53 | |
| RA1931 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 982.0 | 49 | |
| N2586 | 5z-7-oxozeaenol | 0.6 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 101.0 | 62 | |
| N2586 | IKK16 | 2.0 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 839.0 | 50 | |
| RA1869 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 7087.0 | 40 | |
| RA1869 | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 7307.0 | 55 | ||||
| N2759 | Tofacitinib | 0.3 | uM | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 7022.0 | 55 | |
| N2759 | IL-1 alpha | 100 | ng/mL | 3 | MCP-1 (MCAF) | 6754.5 | 60 |